JP2016128399A5 - - Google Patents

Download PDF

Info

Publication number
JP2016128399A5
JP2016128399A5 JP2015118495A JP2015118495A JP2016128399A5 JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 2016128399 A5 JP2016128399 A5 JP 2016128399A5
Authority
JP
Japan
Prior art keywords
amino
lipophilic
amino acids
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015118495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016128399A (ja
JP6767096B2 (ja
Filing date
Publication date
Priority claimed from GBGB1506127.8A external-priority patent/GB201506127D0/en
Application filed filed Critical
Priority to PT157937467T priority Critical patent/PT3230318T/pt
Priority to US15/534,800 priority patent/US11083774B2/en
Priority to AU2015359881A priority patent/AU2015359881B2/en
Priority to ES15793746T priority patent/ES2819282T3/es
Priority to DK15793746.7T priority patent/DK3230318T3/da
Priority to PCT/EP2015/075722 priority patent/WO2016091487A1/en
Priority to HUE15793746A priority patent/HUE051268T2/hu
Priority to LTEP15793746.7T priority patent/LT3230318T/lt
Priority to PL15793746T priority patent/PL3230318T3/pl
Priority to EP15793746.7A priority patent/EP3230318B1/en
Publication of JP2016128399A publication Critical patent/JP2016128399A/ja
Publication of JP2016128399A5 publication Critical patent/JP2016128399A5/ja
Priority to AU2019203199A priority patent/AU2019203199B2/en
Publication of JP6767096B2 publication Critical patent/JP6767096B2/ja
Application granted granted Critical
Priority to AU2021204356A priority patent/AU2021204356B2/en
Priority to US17/366,463 priority patent/US20230201305A9/en
Priority to US18/598,719 priority patent/US12239686B2/en
Priority to US19/022,157 priority patent/US20250332217A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015118495A 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ Active JP6767096B2 (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
LTEP15793746.7T LT3230318T (lt) 2014-12-11 2015-11-04 Imuninės kontrolės taško inhibitorių kombinacijos
EP15793746.7A EP3230318B1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
US15/534,800 US11083774B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
AU2015359881A AU2015359881B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
ES15793746T ES2819282T3 (es) 2014-12-11 2015-11-04 Combinaciones de inhibidores de puntos de control inmunitarios
DK15793746.7T DK3230318T3 (da) 2014-12-11 2015-11-04 Immune checkpoint-inhibitor-kombinationer
PCT/EP2015/075722 WO2016091487A1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
HUE15793746A HUE051268T2 (hu) 2014-12-11 2015-11-04 Immunellenõrzõpont-gátló kombinációk
PT157937467T PT3230318T (pt) 2014-12-11 2015-11-04 Combinações de inibidores de pontos de controlo imunitários
PL15793746T PL3230318T3 (pl) 2014-12-11 2015-11-04 Kombinacje inhibitora immunologicznego punktu kontrolnego
AU2019203199A AU2019203199B2 (en) 2014-12-11 2019-05-07 Immune checkpoint inhibitor combinations
AU2021204356A AU2021204356B2 (en) 2014-12-11 2021-06-25 Immune checkpoint inhibitor combinations
US17/366,463 US20230201305A9 (en) 2014-12-11 2021-07-02 Immune checkpoint inhibitor combinations
US18/598,719 US12239686B2 (en) 2014-12-11 2024-03-07 Immune checkpoint inhibitor combinations
US19/022,157 US20250332217A1 (en) 2014-12-11 2025-01-15 Immune checkpoint inhibitor combinations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201422084 2014-12-11
GB1422084.2 2014-12-11
GB1506127.8 2015-04-10
GBGB1506127.8A GB201506127D0 (en) 2015-04-10 2015-04-10 Immune checkpoint inhibitor combinations

Publications (3)

Publication Number Publication Date
JP2016128399A JP2016128399A (ja) 2016-07-14
JP2016128399A5 true JP2016128399A5 (enExample) 2018-05-10
JP6767096B2 JP6767096B2 (ja) 2020-10-14

Family

ID=56384106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015118495A Active JP6767096B2 (ja) 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ

Country Status (11)

Country Link
US (4) US11083774B2 (enExample)
EP (1) EP3230318B1 (enExample)
JP (1) JP6767096B2 (enExample)
AU (3) AU2015359881B2 (enExample)
DK (1) DK3230318T3 (enExample)
ES (1) ES2819282T3 (enExample)
HU (1) HUE051268T2 (enExample)
LT (1) LT3230318T (enExample)
PL (1) PL3230318T3 (enExample)
PT (1) PT3230318T (enExample)
WO (1) WO2016091487A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
CN110214028A (zh) * 2016-12-26 2019-09-06 国立大学法人神户大学 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
WO2018188761A1 (en) * 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
WO2019240218A1 (ja) 2018-06-14 2019-12-19 株式会社明治 免疫チェックポイント阻害療法を促進するための組成物
CA3139526A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
KR102841588B1 (ko) 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
CN110317245B (zh) * 2019-08-02 2021-04-09 郑州大学 Lag-3蛋白亲和环肽及其应用
CA3152714A1 (en) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
PH12022550876A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
JP2026501255A (ja) 2022-12-20 2026-01-14 リティックス バイオファーマ エイエス 組成物および使用
WO2024133580A1 (en) 2022-12-20 2024-06-27 Lytix Biopharma As Medical products containing an aqueous formulation of a peptide
CN117402828A (zh) * 2023-04-13 2024-01-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种人肺癌脑转移瘤细胞系及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
KR20010043331A (ko) 1998-05-04 2001-05-25 토마스 제퍼슨 유니버시티 종양 세포 및 추출물을 포함하는 조성물 및 이를 이용한방법
GB0605685D0 (en) 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
EP2206517B1 (en) * 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
GB0821616D0 (en) * 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN102740887B (zh) * 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US9410206B2 (en) * 2011-11-30 2016-08-09 John Wayne Cancer Institute Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
BR112016018891A2 (pt) * 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
MX2017007535A (es) * 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ

Similar Documents

Publication Publication Date Title
JP2016128399A5 (enExample)
CN104853776B (zh) 免疫应答的增强
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JP2018501197A5 (enExample)
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
JP2015504871A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
JP2018530554A5 (enExample)
JP2016527286A5 (enExample)
JP2016539096A5 (enExample)
JP2018522045A5 (enExample)
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
AU2021203564B2 (en) Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors
JP2017503014A5 (enExample)
BR112018001534A2 (pt) inibidor de isocitrato desidrogenase idh1 r132h mutante
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
RU2011123700A (ru) Нонапептид с противоопухолевой активностью
JP2018519324A5 (enExample)
JP2024133495A (ja) 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää